Evercore ISI Resumes Travere Therapeutics (TVTX) at Outperform, 'sales of sparsentan in IgAN will begin to accelerate as we head into year end'
Tweet Send to a Friend
(Updated - September 6, 2023 5:30 AM EDT)
Evercore ISI analyst Liisa Bayko resumes coverage on Travere Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Evercore ISI analyst Liisa Bayko resumes coverage on Travere Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
